Halozyme withdraws $2.1 bln buyout offer for Evotec
Portfolio Pulse from
Halozyme Therapeutics has withdrawn its $2.1 billion buyout offer for Evotec SE due to Evotec's unwillingness to engage in discussions.
November 22, 2024 | 2:15 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Halozyme Therapeutics has retracted its $2.1 billion acquisition proposal for Evotec SE after Evotec showed no interest in discussions.
The withdrawal of the buyout offer may have a neutral short-term impact on Halozyme's stock as the market may have already priced in the potential acquisition. The lack of engagement from Evotec suggests the deal was unlikely to proceed, reducing uncertainty.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80